Jump to ContentJump to Main Navigation
Show Summary Details
More options …

Clinical Chemistry and Laboratory Medicine (CCLM)

Published in Association with the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM)

Editor-in-Chief: Plebani, Mario

Ed. by Gillery, Philippe / Greaves, Ronda / Lackner, Karl J. / Lippi, Giuseppe / Melichar, Bohuslav / Payne, Deborah A. / Schlattmann, Peter


IMPACT FACTOR 2017: 3.556

CiteScore 2017: 2.34

SCImago Journal Rank (SJR) 2017: 1.114
Source Normalized Impact per Paper (SNIP) 2017: 1.188

Online
ISSN
1437-4331
See all formats and pricing
More options …
Volume 53, Issue 3

Issues

The lymphocyte to monocyte ratio in peripheral blood represents a novel prognostic marker in patients with pancreatic cancer

Michael Stotz
  • Corresponding author
  • Division of Clinical Oncology, Department of Medicine, Medical University of Graz, Graz, Austria
  • Research Unit Genetic Epidemiology and Pharmacogenetics, Division of Clinical Oncology, Department of Medicine, Medical University of Graz, Graz, Austria
  • Email
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
/ Joanna Szkandera
  • Division of Clinical Oncology, Department of Medicine, Medical University of Graz, Graz, Austria
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
/ Tatjana Stojakovic
  • Clinical Institute of Medical and Chemical Laboratory Diagnostics, Medical University of Graz, Graz, Austria
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
/ Julia Seidel
  • Division of Clinical Oncology, Department of Medicine, Medical University of Graz, Graz, Austria
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
/ Hellmut Samonigg
  • Division of Clinical Oncology, Department of Medicine, Medical University of Graz, Graz, Austria
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
/ Peter Kornprat / Renate Schaberl-Moser
  • Division of Clinical Oncology, Department of Medicine, Medical University of Graz, Graz, Austria
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
/ Fridericke Seggewies
  • Division of Clinical Oncology, Department of Medicine, Medical University of Graz, Graz, Austria
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
/ Gerald Hoefler / Armin Gerger
  • Division of Clinical Oncology, Department of Medicine, Medical University of Graz, Graz, Austria
  • Research Unit Genetic Epidemiology and Pharmacogenetics, Division of Clinical Oncology, Department of Medicine, Medical University of Graz, Graz, Austria
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
/ Martin Pichler
  • Division of Clinical Oncology, Department of Medicine, Medical University of Graz, Graz, Austria
  • Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer, Houston, USA
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
Published Online: 2014-11-08 | DOI: https://doi.org/10.1515/cclm-2014-0447

Abstract

Background: Intra-tumoral macrophages have been involved as important players in the pathogenesis and progression of cancer. Recently, inflammatory parameters of the systemic inflammatory response have also been proposed as usefully prognostic biomarkers. One of these, the lymphocyte to monocyte ratio (LMR) in peripheral blood has been shown as a prognostic factor in hematologic and some solid tumors. In this study we analyzed for the first time the prognostic value of LMR in a large middle European cohort of pancreatic cancer (PC) patients.

Methods: Data from 474 consecutive patients with ductal adenocarcinoma of the pancreas were evaluated retrospectively. Cancer-specific survival (CSS) was analyzed using the Kaplan-Meier method. To further evaluate the prognostic significance of the LMR, univariate and multivariate Cox regression models were calculated.

Results: Increased LMR at diagnosis was significantly associated with well-established prognostic factors, including high tumor stage and tumor grade (p<0.05). In univariate analysis, we observed that an increased LMR was a significant factor for better CSS in PC patients (HR 0.70; 95% CI 0.57–0.85; p<0.001). In multivariate analysis including age, Karnofsky Index, tumor grade, tumor stage, administration of chemotherapy, LMR and surgical resection, we confirmed increased LMR as an independent prognostic factor for CSS (HR 0.81; 95% CI 0.66–0.99; p=0.04).

Conclusions: In conclusion, we identified LMR as an independent prognostic factor in PC patients. Our results indicate that the LMR might represent a novel and useful marker for patient stratification in PC management.

Keywords: inflammation; monocytes; pancreatic cancer; prognosis

References

  • 1.

    Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012;62:10–29.Google Scholar

  • 2.

    Sharma C, Eltawil KM, Renfrew PD, Walsh MJ, Molinari M. Advances in diagnosis, treatment and palliation of pancreatic carcinoma: 1990–2010. World J Gastroenterol 2011;17:867–97.Google Scholar

  • 3.

    Niederhuber JE, Brennan MF, Menck HR. The National Cancer Data Base report on pancreatic cancer. Cancer 1995;76:1671–7.CrossrefPubMedGoogle Scholar

  • 4.

    Kothari N, Saif MW, Kim R. First-line treatment for advanced pancreatic cancer. JOP 2013;14:129–32.PubMedGoogle Scholar

  • 5.

    Saif MW. Advancements in the management of pancreatic cancer: 2013. JOP 2013;14:112–8.PubMedGoogle Scholar

  • 6.

    Tinchon C, Hubmann E, Pichler A, Keil F, Pichler M, Rabl H, et al. Safety and efficacy of neoadjuvant FOLFIRINOX treatment in a series of patients with borderline resectable pancreatic ductal adenocarcinoma. Acta Oncol 2013;52:1231–3.CrossrefGoogle Scholar

  • 7.

    Heinemann V, Haas M, Boeck S. Neoadjuvant treatment of borderline resectable and non-resectable pancreatic cancer. Ann Oncol 2013;24:2484–92.PubMedCrossrefGoogle Scholar

  • 8.

    Raut CP, Tseng JF, Sun CC, Wang H, Wolff RA, Crane CH, et al. Impact of resection status on pattern of failure and survival after pancreaticoduodenectomy for pancreatic adenocarcinoma. Ann Surg 2007;246:52–60.Google Scholar

  • 9.

    Stotz M, Eisner F, Szkandera J, Absenger G, Kornprat P, Lackner C, et al. Clinico-pathological characteristics and clinical outcome of different histological types of pancreatic cancer in a large Middle European series. J Clin Pathol 2013;66:753–7.CrossrefGoogle Scholar

  • 10.

    Szkandera J, Gerger A, Liegl-Atzwanger B, Absenger G, Stotz M, Samonigg H, et al. Validation of the prognostic relevance of plasma C-reactive protein levels in soft-tissue sarcoma patients. Br J Cancer 2013;109:2316–22.CrossrefGoogle Scholar

  • 11.

    Dalpiaz O, Ehrlich GC, Mannweiler S, Hernandez JM, Gerger A, Stojakovic T, et al. Validation of pretreatment neutrophil-lymphocyte ratio as a prognostic factor in a European cohort of patients with upper tract urothelial carcinoma. Br J Urol Int 2013;114:334–9.Google Scholar

  • 12.

    Pichler M, Hutterer GC, Stojakovic T, Mannweiler S, Pummer K, Zigeuner R. High plasma fibrinogen level represents an independent negative prognostic factor regarding cancer-specific, metastasis-free, as well as overall survival in a European cohort of non-metastatic renal cell carcinoma patients. Br J Cancer 2013;109:1123–9.CrossrefGoogle Scholar

  • 13.

    Absenger G, Szkandera J, Pichler M, Stotz M, Arminger F, Weissmueller M, et al. A derived neutrophil to lymphocyte ratio predicts clinical outcome in stage II and III colon cancer patients. Br J Cancer 2013;109:395–400.CrossrefGoogle Scholar

  • 14.

    Szkandera J, Pichler M, Liegl-Atzwanger B, Absenger G, Stotz M, Ploner F, et al. The elevated pre-operative plasma fibrinogen level is an independent negative prognostic factor for cancer-specific, disease-free and overall survival in soft-tissue sarcoma patients. J Surg Oncol [Epub ahead of print 2013 Oct 7]. doi: 10.1002/jso.23458.CrossrefGoogle Scholar

  • 15.

    Porrata LF, Ristow K, Colgan JP, Habermann TM, Witzig TE, Inwards DJ, et al. Peripheral blood lymphocyte/monocyte ratio at diagnosis and survival in classical Hodgkin’s lymphoma. Haematologica 2012;97:262–9.CrossrefGoogle Scholar

  • 16.

    Li ZM, Huang JJ, Xia Y, Sun J, Huang Y, Wang Y, et al. Blood lymphocyte-to-monocyte ratio identifies high-risk patients in diffuse large B-cell lymphoma treated with R-CHOP. PLoS One 2012;7:e41658.PubMedGoogle Scholar

  • 17.

    Wei X, Huang F, Wei Y, Jing H, Xie M, Hao X, et al. Low lymphocyte-to-monocyte ratio predicts unfavorable prognosis in non-germinal center type diffuse large B-cell lymphoma. Leuk Res 2014;38:694–8.CrossrefPubMedGoogle Scholar

  • 18.

    Markovic O, Popovic L, Marisavljevic D, Jovanovic D, Filipovic B, Stanisavljevic D, et al. Comparison of prognostic impact of absolute lymphocyte count, absolute monocyte count, absolute lymphocyte count/absolute monocyte count prognostic score and ratio in patients with diffuse large B cell lymphoma. Eur J Intern Med 2014;25:296–302.CrossrefPubMedGoogle Scholar

  • 19.

    Porrata LF, Ristow KM, Habermann TM, Witzig TE, Colgan JP, Inwards DJ, et al. Peripheral blood absolute lymphocyte/monocyte ratio during rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone treatment cycles predicts clinical outcomes in diffuse large B-cell lymphoma. Leuk Lymphoma [Epub ahead of print 2014 Mar 19]. doi: 10.3109/10428194.2014.893313.CrossrefGoogle Scholar

  • 20.

    Yan-Li L, Kang-Sheng G, Yue-Yin P, Yang J, Zhi-Min Z. The lower peripheral blood lymphocyte/monocyte ratio assessed during routine follow-up after standard first-line chemotherapy is a risk factor for predicting relapse in patients with diffuse large B-cell lymphoma. Leuk Res 2014;38:323–8.CrossrefGoogle Scholar

  • 21.

    Watanabe R, Tomita N, Itabashi M, Ishibashi D, Yamamoto E, Koyama S et al. Peripheral blood absolute lymphocyte/monocyte ratio as a useful prognostic factor in diffuse large B-cell lymphoma in the rituximab era. Eur J Haematol 2014;92:204–10.CrossrefPubMedGoogle Scholar

  • 22.

    Kumagai S, Tashima M, Fujikawa J, Iwasaki M, Iwamoto Y, Sueki Y, et al. Ratio of peripheral blood absolute lymphocyte count to absolute monocyte count at diagnosis is associated with progression-free survival in follicular lymphoma. Int J Hematol 2014;99:732–42.Google Scholar

  • 23.

    Shin SJ, Roh J, Kim M, Jung MJ, Koh YW, Park CS, et al. Prognostic significance of absolute lymphocyte count/absolute monocyte count ratio at diagnosis in patients with multiple myeloma. Korean J Pathol 2013;47:526–33.CrossrefPubMedGoogle Scholar

  • 24.

    Koh YW, Park CS, Yoon DH, Suh C, Huh J. Should the cut-off values of the lymphocyte to monocyte ratio for prediction of prognosis in diffuse large B-cell lymphoma be changed in elderly patients? Eur J Haematol 2014;93:340–8.PubMedCrossrefGoogle Scholar

  • 25.

    Li J, Jiang R, Liu WS, Liu Q, Xu M, Feng QS, et al. A large cohort study reveals the association of elevated peripheral blood lymphocyte-to-monocyte ratio with favorable prognosis in nasopharyngeal carcinoma. PLoS One 2013;8:e83069.PubMedGoogle Scholar

  • 26.

    Stotz M, Pichler M, Absenger G, Szkandera J, Arminger F, Schaberl-Moser R, et al. The preoperative lymphocyte to monocyte ratio predicts clinical outcome in patients with stage III colon cancer. Br J Cancer 2014;110:435–40.CrossrefGoogle Scholar

  • 27.

    Szkandera J, Gerger A, Liegl-Atzwanger B, Absenger G, Stotz M, Friesenbichler J, et al. The lymphocyte/monocyte ratio predicts poor clinical outcome and improves the predictive accuracy in patients with soft tissue sarcomas. Int J Cancer 2014;135:362–70.Google Scholar

  • 28.

    Roth AD, Tejpar S, Delorenzi M, Yan P, Fiocca R, Klingbiel D, et al. Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial. J Clin Oncol 2010;28:466–74.Google Scholar

  • 29.

    Stotz M, Gerger A, Eisner F, Szkandera J, Loibner H, Ress AL, et al. Increased neutrophil-lymphocyte ratio is a poor prognostic factor in patients with primary operable and inoperable pancreatic cancer. Br J Cancer 2013;109:416–21.CrossrefGoogle Scholar

  • 30.

    Zikos TA, Donnenberg AD, Landreneau RJ, Luketich JD, Donnenberg VS. Lung T-cell subset composition at the time of surgical resection is a prognostic indicator in non-small cell lung cancer. Cancer Immunol Immunother 2011;60:819–27.CrossrefGoogle Scholar

  • 31.

    Rosenberg SA. Progress in human tumour immunology and immunotherapy. Nature 2001;411:380–4.CrossrefPubMedGoogle Scholar

  • 32.

    Hoffmann TK, Dworacki G, Tsukihiro T, Meidenbauer N, Gooding W, Johnson JT, et al. Spontaneous apoptosis of circulating T lymphocytes in patients with head and neck cancer and its clinical importance. Clin Cancer Res 2002;8:2553–62.PubMedGoogle Scholar

  • 33.

    Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature 2008;454:436–44.PubMedCrossrefGoogle Scholar

  • 34.

    Hutterer GC, Pichler M, Chromecki TF, Strini KA, Klatte T, Pummer K, et al. Tumour-associated macrophages might represent a favourable prognostic indicator in patients with papillary renal cell carcinoma. Histopathology 2013;63:309–15.CrossrefPubMedGoogle Scholar

  • 35.

    Bingle L, Brown NJ, Lewis CE. The role of tumour-associated macrophages in tumour progression: implications for new anticancer therapies. J Pathol 2002;196:254–65.PubMedCrossrefGoogle Scholar

  • 36.

    Pollard JW. Tumour-educated macrophages promote tumour progression and metastasis. Nat Rev Cancer 2004;4:71–8.CrossrefPubMedGoogle Scholar

  • 37.

    Condeelis J, Pollard JW. Macrophages: obligate partners for tumor cell migration, invasion, and metastasis. Cell 2006;124:263–6.PubMedCrossrefGoogle Scholar

  • 38.

    Pollard JW. Trophic macrophages in development and disease. Nat Rev Immunol 2009;9:259–70.PubMedCrossrefGoogle Scholar

  • 39.

    Mroczko B, Groblewska M, Wereszczynska-Siemiatkowska U, Okulczyk B, Kedra B, Laszewicz W, et al. Serum macrophage-colony stimulating factor levels in colorectal cancer patients correlate with lymph node metastasis and poor prognosis. Clin Chim Acta 2007;380:208–12.Google Scholar

  • 40.

    Evani SJ, Prabhu RG, Gnanaruban V, Finol EA, Ramasubramanian AK. Monocytes mediate metastatic breast tumor cell adhesion to endothelium under flow. FASEB J 2013;27:3017–29.PubMedCrossrefGoogle Scholar

  • 41.

    Saccani A, Schioppa T, Porta C, Biswas SK, Nebuloni M, Vago L, et al. p50 nuclear factor-kappaB overexpression in tumor-associated macrophages inhibits M1 inflammatory responses and antitumor resistance. Cancer Res 2006;66:11432–40.CrossrefGoogle Scholar

  • 42.

    Galdiero MR, Bonavita E, Barajon I, Garlanda C, Mantovani A, Jaillon S. Tumor associated macrophages and neutrophils in cancer. Immunobiology 2013;218:1402–10.CrossrefPubMedGoogle Scholar

  • 43.

    Yang Y, Qin J, Lan L, Li N, Wang C, He P, et al. M-CSF cooperating with NF-kB induces macrophage transformation from M1 to M2 by up-regulating c-Jun. Cancer Biol Ther 2013;15:99–107.Google Scholar

  • 44.

    Partecke LI, Gunther C, Hagemann S, Jacobi C, Merkel M, Sendler M, et al. Induction of M2-macrophages by tumour cells and tumour growth promotion by M2-macrophages: a quid pro quo in pancreatic cancer. Pancreatology 2013;13:508–16.CrossrefPubMedGoogle Scholar

  • 45.

    Lin EY, Li JF, Gnatovskiy L, Deng Y, Zhu L, Grzesik DA, et al. Macrophages regulate the angiogenic switch in a mouse model of breast cancer. Cancer Res 2006;66:11238–46.CrossrefGoogle Scholar

  • 46.

    Jetten N, Verbruggen S, Gijbels MJ, Post MJ, De Winther MP, Donners MM. Anti-inflammatory M2, but not pro-inflammatory M1 macrophages promote angiogenesis in vivo. Angiogenesis 2014;17:109–18.PubMedCrossrefGoogle Scholar

  • 47.

    Swann JB, Vesely MD, Silva A, Sharkey J, Akira S, Schreiber RD, et al. Demonstration of inflammation-induced cancer and cancer immunoediting during primary tumorigenesis. Proc Natl Acad Sci USA 2008;105:652–6.CrossrefGoogle Scholar

  • 48.

    Weizman N, Krelin Y, Shabtay-Orbach A, Amit M, Binenbaum Y, Wong RJ, et al. Macrophages mediate gemcitabine resistance of pancreatic adenocarcinoma by upregulating cytidine deaminase. Oncogene 2014;33:3812–9.PubMedCrossrefGoogle Scholar

  • 49.

    Batty N, Ghonimi E, Feng L, Fayad L, Younes A, Rodriguez MA, et al. The absolute monocyte and lymphocyte prognostic index for patients with diffuse large B-cell lymphoma who receive R-CHOP. Clin Lymphoma Myeloma Leuk 2013;13:15–8.CrossrefPubMedGoogle Scholar

  • 50.

    Porrata LF, Ristow K, Habermann TM, Witzig TE, Colgan JP, Inwards DJ, et al. Peripheral blood lymphocyte/monocyte ratio at diagnosis and survival in nodular lymphocyte-predominant Hodgkin lymphoma. Br J Haematol 2012;157:321–30.Google Scholar

  • 51.

    Christians KK, Tsai S, Mahmoud A, Ritch P, Thomas JP, Wiebe L, et al. Neoadjuvant FOLFIRINOX for borderline resectable pancreas cancer: a new treatment paradigm? Oncologist 2014;19:266–74.CrossrefPubMedGoogle Scholar

  • 52.

    Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med 2013;369:1691–703.Google Scholar

  • 53.

    Alonzo TA. Standards for reporting prognostic tumor marker studies. J Clin Oncol 2005;23:9053–4.CrossrefGoogle Scholar

  • 54.

    McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM, et al. Reporting recommendations for tumor marker prognostic studies. J Clin Oncol 2005;23:9067–72.CrossrefGoogle Scholar

About the article

Corresponding author: Michael Stotz, Division of Clinical Oncology, Department of Medicine, Medical University of Graz, Auenbruggerplatz 15, 8036 Graz, Austria, Phone: +43 316 385 13115, Fax: +43 316 385 13355, E-mail: ; and Research Unit Genetic Epidemiology and Pharmacogenetics, Division of Clinical Oncology, Department of Medicine, Medical University of Graz, Graz, Austria


Received: 2014-04-25

Accepted: 2014-10-13

Published Online: 2014-11-08

Published in Print: 2015-02-01


Citation Information: Clinical Chemistry and Laboratory Medicine (CCLM), Volume 53, Issue 3, Pages 499–506, ISSN (Online) 1437-4331, ISSN (Print) 1434-6621, DOI: https://doi.org/10.1515/cclm-2014-0447.

Export Citation

©2015 by De Gruyter.Get Permission

Citing Articles

Here you can find all Crossref-listed publications in which this article is cited. If you would like to receive automatic email messages as soon as this article is cited in other publications, simply activate the “Citation Alert” on the top of this page.

[1]
Konstantin Schlick, Teresa Magnes, Lukas Ratzinger, Bernhard Jaud, Lukas Weiss, Thomas Melchardt, Richard Greil, Alexander Egle, and Aamir Ahmad
PLOS ONE, 2018, Volume 13, Number 11, Page e0206688
[2]
Eva Asamer, Joanna Szkandera, Paul Gibiser, Anna Lena Lembeck, Tatjana Stojakovic, Peter Kornprat, Caroline Lackner, Thomas Winder, Konstantin Schlick, Herbert Stöger, Armin Gerger, Martin Pichler, and Michael Stotz
Wiener klinische Wochenschrift, 2018
[3]
Mounsif Azizi, Charles C. Peyton, David C. Boulware, Juan Chipollini, Timothy Juwono, Julio M. Pow-Sang, and Philippe E. Spiess
European Urology Focus, 2018
[4]
Lawrence J. Oh, Eugene Wong, Juliana Andrici, Peter McCluskey, James E. H. Smith, and Anthony J. Gill
Internal Medicine Journal, 2018, Volume 48, Number 4, Page 408
[5]
Ru-jin Hu, Jian-ying Ma, and Gang Hu
Clinica Chimica Acta, 2018, Volume 481, Page 142
[6]
Wendi Li, Lianyuan Tao, Meng Lu, and Dianrong Xiu
Medicine, 2018, Volume 97, Number 8, Page e9616
[7]
Ning Pu, Yang Lv, Guochao Zhao, Wanling Lee, Abulimiti Nuerxiati, Dansong Wang, Xuefeng Xu, Tiantao Kuang, Wenchuan Wu, and Wenhui Lou
Future Oncology, 2017
[8]
Peng Xue, Junjie Hang, Weiyi Huang, Shaobo Li, Ning Li, Yuzo Kodama, Shigemi Matsumoto, Kyoichi Takaori, Lifei Zhu, and Masashi Kanai
Pancreas, 2017, Volume 46, Number 8, Page 1011
[10]
Minyong Kang, Chang Wook Jeong, Cheol Kwak, Hyeon Hoe Kim, and Ja Hyeon Ku
Clinical Genitourinary Cancer, 2017, Volume 15, Number 4, Page e633
[11]
Crystel M Gijsberts, Guilielmus HJM Ellenbroek, Maarten J ten Berg, Albert Huisman, Wouter W van Solinge, Folkert W Asselbergs, Hester M den Ruijter, Gerard Pasterkamp, Dominique PV de Kleijn, and Imo E Hoefer
European Journal of Preventive Cardiology, 2016, Volume 23, Number 11, Page 1211
[12]
Are Naess, Siri Saervold Nilssen, Reidun Mo, Geir Egil Eide, and Haakon Sjursen
Infection, 2017, Volume 45, Number 3, Page 299
[13]
Alexey A. Leontovich, Roxana S. Dronca, Wendy K. Nevala, Michael A. Thompson, Lisa A. Kottschade, Leonid V. Ivanov, and Svetomir N. Markovic
Melanoma Research, 2017, Volume 27, Number 1, Page 32
[14]
ShaoMing Zhu, Yulituzi Waili, XiaoTing Qi, YueMei Chen, and YuFeng Lou
European Journal of Gastroenterology & Hepatology, 2017, Volume 29, Number 1, Page 31
[15]
Marek Sierzega, Marzena Lenart, Magdalena Rutkowska, Marta Surman, Bozenna Mytar, Andrzej Matyja, Maciej Siedlar, and Jan Kulig
Annals of Surgical Oncology, 2017, Volume 24, Number 3, Page 808
[16]
Bernard Tawfik, Ali A. Mokdad, Prachi M. Patel, Hsiao C. Li, and Sergio Huerta
Anti-Cancer Drugs, 2016, Volume 27, Number 9, Page 879
[17]
Honggang Xia, Zhongyi Sun, Limin Deng, Deqing Zhu, and Dongbin Wang
Cancer Investigation, 2016, Volume 34, Number 8, Page 378
[18]
Liang Chen, Fang Zhang, Xiu-gui Sheng, Shi-qian Zhang, Yue-ting Chen, and Bo-wen Liu
Medicine, 2016, Volume 95, Number 32, Page e4381
[19]
Jingwen Zhang, Lishan Chen, Rui Zhou, Huiying Sun, Yulin Liao, and Wangjun Liao
Gastroenterology Research and Practice, 2016, Volume 2016, Page 1
[20]
Jun Kasuga, Takashi Kawahara, Daiji Takamoto, Sachi Fukui, Takashi Tokita, Tomoyuki Tadenuma, Masaki Narahara, Syusei Fusayasu, Hideyuki Terao, Koji Izumi, Hiroki Ito, Yusuke Hattori, Jun-ichi Teranishi, Takeshi Sasaki, Kazuhide Makiyama, Yasuhide Miyoshi, Masahiro Yao, Yasushi Yumura, Hiroshi Miyamoto, and Hiroji Uemura
BMC Cancer, 2016, Volume 16, Number 1
[21]
Si-wei Li, Wenxin Yuan, Bo Zhao, Zhuo-kai He, Xiang Guo, Wei-xiong Xia, and Li-hua Xu
Cancer Cell International, 2016, Volume 16, Number 1
[22]
Jie Zhang, Guofang Feng, Ying Zhao, Juanwen Zhang, Limin Feng, and Jing Yang
BMJ Open, 2015, Volume 5, Number 8, Page e008033
[23]
Yu-Mu Chen, Chien-Hao Lai, Huang-Chih Chang, Tung-Ying Chao, Chia-Cheng Tseng, Wen-Feng Fang, Chin-Chou Wang, Yu-Hsiu Chung, Yi-Hsi Wang, Mao-Chang Su, Kuo-Tung Huang, Hung-cheng Chen, and Meng-Chih Lin
Lung Cancer, 2016, Volume 93, Page 47
[24]
Sergio Huerta and Prachi Patel
Journal of the American College of Surgeons, 2015, Volume 221, Number 5, Page 996
[25]
Tomohiro F. Nishijima, Hyman B. Muss, Shlomit S. Shachar, Kazuo Tamura, and Yasushi Takamatsu
Cancer Treatment Reviews, 2015, Volume 41, Number 10, Page 971
[26]
Wei Sun, Linli Zhang, Min Luo, Guangyuan Hu, Qi Mei, Dongbo Liu, Guoxian Long, and Guoqing Hu
Head & Neck, 2016, Volume 38, Number S1, Page E1332
[27]
Tsuyoshi Ozawa, Soichiro Ishihara, Kazushige Kawai, Shinsuke Kazama, Hironori Yamaguchi, Eiji Sunami, Joji Kitayama, and Toshiaki Watanabe
Journal of Surgical Research, 2015, Volume 199, Number 2, Page 386
[28]
Qing Chen, Liu-Xiao Yang, Xue-Dong Li, Dan Yin, Shi-Ming Shi, Er-Bao Chen, Lei Yu, Zheng-Jun Zhou, Shao-Lai Zhou, Ying-Hong Shi, Jia Fan, Jian Zhou, and Zhi Dai
Tumor Biology, 2015, Volume 36, Number 7, Page 5283

Comments (0)

Please log in or register to comment.
Log in